Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
4 hedge funds and large institutions have $1.39K invested in Hepion Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 15 closing their positions.
75% less funds holding
Funds holding: 16 → 4 (-12)
80% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 15
100% less capital invested
Capital invested by funds: $420K → $1.39K (-$418K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$6.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$360K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$45.4K |
| 3 |
HF
HRT Financial
New York
|
-$7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$6.7K |
| 5 |
BlackRock
New York
|
-$713 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
XT
1
XTX Topco
George Town,
Cayman Islands
| $1.39K | +$6.27K | +17,361 | New |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| – | -$360K | -836,615 | Closed |
|
|
AFM
3
Anson Funds Management
Dallas,
Texas
| – | -$45.4K | -105,685 | Closed |
|
|
HF
4
HRT Financial
New York
| – | -$7K | -16,387 | Closed |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$6.7K | -15,581 | Closed |
|
|
6
BlackRock
New York
| – | -$713 | -1,658 | Closed |
|
7
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$67 | -156 | Closed |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| – | -$47 | -110 | Closed |
|
9
Fidelity Investments
Boston,
Massachusetts
| – | -$43 | -100 | Closed |
|
|
SS
10
SBI Securities
Tokyo,
Japan
| – | -$14 | -32 | Closed |
|
11
Morgan Stanley
New York
| – | -$13 | -30 | Closed |
|
12
Group One Trading
Chicago,
Illinois
| – | -$2 | -4 | Closed |
|
|
FDCDDQ
13
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$1 | -3 | Closed |
|
|
AF
14
Allworth Financial
Folsom,
California
| – | -$1 | -1 | Closed |
|
HEPA Hedge Fund Activity: Q2 2025 in Review
4 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q2 2025, worth a combined $1.39K — down 100% from $420K a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of HEPA and 3 opened new positions — a net loss of 12 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was XTX Topco, opening a new position worth an estimated $6.27K. The largest seller was Sabby Management, exiting entirely with an estimated $360K sold.
- 4 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q2 2025, down from 16 in Q1 2025.
- Funds reported $1.39K of Hepion Pharmaceuticals stock for Q2 2025, down 100% quarter-over-quarter.
- 3 funds opened new Hepion Pharmaceuticals positions in Q2 2025 and 15 closed out, a net change of -12 holders.
- The largest Hepion Pharmaceuticals buyer in Q2 2025 was XTX Topco, an estimated $6.27K added.
- The largest Hepion Pharmaceuticals seller in Q2 2025 was Sabby Management, an estimated $360K sold.
Based on aggregated 13F filings for Q2 2025.